



A patent dedicated for generation of anti-cancer vaccines against Non-Small Cell Lung Cancer (NSCLC)

About technology


Immunoprecipitation (IP) is a widely used method to screen the neoantigen. However this approach has technical limitations such as antibody dependant/biased, costly, time-consuming and inability to employ for other than the human model due to lack of efficient antibodies.

The method has been applied as a **mild acid** elution approach to salivary gland patient tissues for screening and quantification of neoantigens. The novel approach facilitates the screening of neoantigens directly from patient samples, such as tumours. Moreover, it is a rapid, low-cost, simple, high-throughput, antibody-independent and reproducible approach that can be used worldwide. The **tumour** approach ultimately opens a wide door for the development and improvement of immunotherapies for humans and animal models, such as dogs, pigs, for many diseases or health problems (cancer, autoimmune diseases, viral and infectious diseases, etc.).

The method has great potential to open up many branches for various diseases, many of which rely on immune response and grown in **academic, medical, biotechnological and industrial** development.

Implementation progress

TRL 4 –Technology validated in laboratory conditions



Research Team

Natalia Marek-Trzonkowska, prof.
Paulina Czaplewska, prof. UG, dr hab.
Sachin Kote, PhD
Jakub Faktor, PhD
Artur Piróg, PhD

IP Protection

The invention is the subject of an European patent application:
**EP23182546 and
PCT/EP2023/085829**

Cooperation opportunities

- Licensing agreement
- Transfer of ownership
- Spin off

